VAP Test Improves Identification of CIMT Progression
BIRMINGHAM, Ala.–()–Expanded cholesterol assessment of moderate risk patients can play an
important role in identifying and monitoring the progression of
atherosclerosis. That’s according to a clinical study that used the VAP®
(Vertical Auto Profile) Cholesterol Test to analyze lipids potentially
associated with carotid intima-media thickness (CIMT).
“A closer look at these moderate CHD risk patients found that use of the
VAP expanded cholesterol assessment can play an important role to more
accurately identify and monitor the progression of atherosclerosis as
measured by CIMT progression”
The study Indicators
of the Atherogenic Lipoprotein Phenotype Measured with Density Gradient
Ultracentrifugation Predict Changes in Carotid Intima-Media Thickness in
Men and Women by Maki et al was published in the January 2012 issue
of Vascular Health and Risk Management. The sub-analysis
demonstrated that using the VAP Test density gradient
ultracentrifugation (DGU) method, researchers were able to get a
detailed look at how lipoproteins and their subfractions were associated
with CIMT progression in men and women at moderate coronary heart
disease (CHD) risk.
“A closer look at these moderate CHD risk patients found that use of the
VAP expanded cholesterol assessment can play an important role to more
accurately identify and monitor the progression of atherosclerosis as
measured by CIMT progression,” said Kevin C. Maki, Ph.D., study lead
author and president and chief scientific officer at Provident Clinical
Research/Biofortis North America. “Density gradient ultracentrifugation
clearly provides a level of clinical detail about lipids and
subfractions not available from the standard lipid profile.”
The Maki et al study analyzed subjects from the control arm of an
earlier double-blind, randomized, clinical trial designed to evaluate
the effects of consumption of pomegranate juice compared to a control
beverage on CIMT over a period of 18 months. Researchers investigated
the relationships between baseline lipoprotein cholesterol, triglyceride
(TG) and apolipoprotein B (apoB) levels assessed with the VAP Test and
progression of posterior wall common CIMT in men and women at moderate
risk of CHD.
Researchers reported that higher levels of TG-rich lipoprotein
cholesterol, lower levels of HDL and HDL subfractions, and a greater
proportion of LDL carried by more dense LDL particles were associated
with CIMT progression in men and women at moderate risk for CHD. The
atherogenic lipoprotein phenotype identified by the VAP Test is more
strongly associated with CIMT progression than LDL, Non-HDL and apoB
concentrations.
The atherogenic phenotype may have an important role in the initiation
and progression of early atherosclerosis, and Maki said the data should
provide clinicians with useful information to better predict CHD risk
and more clearly understand the importance of measurement of lipoprotein
subspecies.
The VAP Test is a direct and comprehensive measurement of cholesterol
markers associated with heart disease, providing accurate information
that can effectively identify and target risk in clinical care. The VAP
Test identifies a significantly greater number of people at risk for
heart disease than the standard cholesterol test.
Atherotech Diagnostics Lab provides physicians with a single source for
the VAP Test and more than 50 other cardiovascular and metabolic tests.
The company provides its unique testing services to physicians,
hospitals, clinics and other laboratories throughout the U.S.
For information visit www.Atherotech.com
or call 877-901-8510. Atherotech Diagnostics Lab is on Twitter at www.Twitter.com/Atherotech
and also on Facebook at www.Facebook.com/Atherotech.
About Atherotech Diagnostics Lab
Atherotech is a CLIA-certified clinical reference laboratory and
cardiodiagnostic company focusing on cardiometabolic tests, including
the company’s patented VAP Cholesterol Test, which reports the
cholesterol content of all lipids, components and subclasses. The VAP
Test is the first cholesterol profile to comply with updated National
Cholesterol Education Program ATP III recommendations for direct LDL
measurement, which is accurate with non-fasting samples. The VAP Test is
available through national and regional diagnostic laboratories and is
reimbursed by many of the largest private insurers as well as Medicare.
For more information, visit www.Atherotech.com.
Article source: http://eon.businesswire.com/news/eon/20120126005424/en/CIMT-progression/Vap-Test/cholesterol
Filed Under Cholesterol News | Leave a Comment
keep looking »